141 related articles for article (PubMed ID: 3371750)
1. Malignant pericardial effusion in ovarian carcinoma cured by systemic chemotherapy.
Mäenpää J; Taina E; Erkkola R
Gynecol Oncol; 1988 Jun; 30(2):298-301. PubMed ID: 3371750
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of pseudomyxoma peritonei of ovarian origin with cis-platinum, doxorubicin, and cyclophosphamide.
Jones CM; Homesley HD
Gynecol Oncol; 1985 Oct; 22(2):257-9. PubMed ID: 4054721
[TBL] [Abstract][Full Text] [Related]
3. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
4. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer.
Vriesendorp R; Aalders JG; Sleijfer DT; Postmus PE; Willemse PH; Bouma J; Mulder NH
Gynecol Oncol; 1984 Mar; 17(3):271-6. PubMed ID: 6368331
[TBL] [Abstract][Full Text] [Related]
5. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
Mäenpää J
Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
[TBL] [Abstract][Full Text] [Related]
6. Multimodal approach to the treatment of stage III ovarian carcinoma: preliminary report of a pilot study and critical review.
Paule B; Frydman R; Chasseray JM
Biomed Pharmacother; 1985; 39(5):241-5. PubMed ID: 4084658
[TBL] [Abstract][Full Text] [Related]
7. Malignant pericardial effusion in endometrial adenocarcinoma.
Hayashi Y; Iwasaka T; Hachisuga T; Kishikawa T; Ikeda N; Sugimori H
Gynecol Oncol; 1988 Feb; 29(2):234-9. PubMed ID: 3338674
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential.
Yazigi R; Munoz AK; Sandstad J; Lifshitz S; Choi DJ
Eur J Gynaecol Oncol; 1991; 12(6):451-5. PubMed ID: 1809577
[TBL] [Abstract][Full Text] [Related]
9. Serum CA 125 in ovarian pathology and its variation in ovarian carcinoma after integrated therapy.
Pansini F; Bellinazzi A; Rainaldi V; Santoiemma M; Lenzi B; Jacobs M; Mollica G; Bagni B
Gynecol Obstet Invest; 1986; 21(1):47-51. PubMed ID: 3005141
[TBL] [Abstract][Full Text] [Related]
10. A case of primary cardiac lymphoma located in the pericardial effusion.
Nakakuki T; Masuoka H; Ishikura K; Seko T; Koyabu S; Tamai T; Sugawa M; Ito M; Nakano T
Heart Vessels; 2004 Jul; 19(4):199-202. PubMed ID: 15278395
[TBL] [Abstract][Full Text] [Related]
11. Lack of substantial five year disease-free survival by primary aggressive surgery and cisplatin-based chemotherapy or by salvage intraperitoneal cisplatin-based chemotherapy.
Piver MS; Baker TR; Driscoll DL
Eur J Gynaecol Oncol; 1990; 11(4):243-50. PubMed ID: 2245807
[No Abstract] [Full Text] [Related]
12. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
Stratton JA; Kucera PR; Rettenmaier MA; Dobashi K; Micha JP; Braly PS; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Nov; 25(3):302-10. PubMed ID: 3781341
[TBL] [Abstract][Full Text] [Related]
13. Recurrent ovarian carcinoma: presentation as idiopathic thrombocytopenic purpura and a splenic mass.
Tarraza HM; Carroll R; De Cain M; Jones M
Eur J Gynaecol Oncol; 1991; 12(6):439-43. PubMed ID: 1809575
[TBL] [Abstract][Full Text] [Related]
14. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
15. Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report.
Micha JP; Goldstein BH; Zusman D; Rettenmaier MA; Epstein HD; Brown JV
J Reprod Med; 2007 Oct; 52(10):971-3. PubMed ID: 17977179
[TBL] [Abstract][Full Text] [Related]
16. Survival after malignant pericardial effusion and cardiac tamponade in advanced ovarian cancer.
Levitan Z; Kaplan AL; Gordon AN
South Med J; 1990 Feb; 83(2):241-2. PubMed ID: 2305307
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report.
Ohara N; Teramoto K
Clin Exp Obstet Gynecol; 2000; 27(2):123-4. PubMed ID: 10968352
[No Abstract] [Full Text] [Related]
19. [A case of malignant pericardial effusion due to breast cancer successfully controlled by intrapericardial chemotherapy using pirarubicin].
Fujito T; Maeura Y; Shimoda M; Hojo S; Yano Y; Matsunaga S
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1757-9. PubMed ID: 11708027
[TBL] [Abstract][Full Text] [Related]
20. New approaches to the management and treatment of malignant pericardial effusion.
Tomkowski W; Szturmowicz M; Fijałkowska A; Burakowski J; Filipecki S
Support Care Cancer; 1997 Jan; 5(1):64-6. PubMed ID: 9010992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
